Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.25%
1,104.10
+2.73
+0.25%
—1,101.371,103.631,105.311,091.41——
SIXC
Communications
SIXC
Communications
SIXC
-1.50%
604.16
-9.19
-1.50%
—613.35613.35613.35601.49——
SIXE
Energy
SIXE
Energy
SIXE
-0.09%
1,197.81
-1.02
-0.09%
—1,198.831,199.681,199.751,182.41——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,740.41
-15.54
-0.88%
—1,755.951,754.061,756.031,734.69——
SIXM
Financials
SIXM
Financials
SIXM
-0.64%
634.44
-4.07
-0.64%
—638.51637.41637.41633.05——
SIXR
Staples
SIXR
Staples
SIXR
-0.31%
840.90
-2.62
-0.31%
—843.52843.35846.40837.93——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.38%
215.13
-0.82
-0.38%
—215.95215.95216.84215.06——
SIXT
Technology
SIXT
Technology
SIXT
+2.86%
3,228.71
+89.80
+2.86%
—3,138.913,189.303,230.853,174.76——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.16%
935.87
+1.50
+0.16%
—934.37934.72938.26927.50——
SIXV
Health care
SIXV
Health care
SIXV
-1.37%
1,457.12
-20.31
-1.37%
—1,477.431,474.121,474.121,451.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.83%
2,399.84
+19.65
+0.83%
—2,380.192,389.342,403.042,380.47——
INDV:NASDAQ
Indivior Pharmaceuticals, Inc
$33.23
+0.21%
(+0.070) 1D
$33.23
0.00% (0.00)
After hours
Closed: Apr 24, 4:00:05 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INDV...
Open
$33.07
High
$33.28
Low
$32.76
Mkt. cap
4.05B
Avg. vol.
2.97M
Volume
824.22K
P/E ratio
20.25
52-wk high
$38.00
52-wk low
$8.92
EPS
$1.64
Beta
1.11
Shares outstanding
121.92M
No. of employees
833
News stories
From sources across the web
Profile
Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market. Wikipedia
About Indivior Pharmaceuticals, Inc
CEOMark Crossley
Employees833
FoundedSep 26, 2014
Headquarters-
SectorPharmaceutical industry
Last report
Feb 26, 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
0.82/ (0.40 est.)USD
+102.47%beat
Revenue / Estimate
358.00M/ (324.30M est.)USD
+10.39%beat
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
266.00M
302.00M
314.00M
358.00M
Cost of goods sold
44.00M
52.00M
46.00M
56.00M
Cost of revenue
44.00M
52.00M
46.00M
56.00M
Research and development expenses
22.00M
21.00M
20.00M
17.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
132.00M
158.00M
133.00M
155.00M
Operating expense
154.00M
179.00M
152.00M
169.00M
Total operating expenses
198.00M
231.00M
198.00M
225.00M
Operating income
68.00M
71.00M
116.00M
133.00M
Other non operating income
-1.00M
-
-1.00M
-
EBT including unusual items
58.00M
62.00M
37.00M
81.00M
EBT excluding unusual items
59.00M
62.00M
109.00M
133.00M
Income tax expense
11.00M
44.00M
-5.00M
-21.00M
Effective tax rate
18.97%
70.97%
-13.51%
-25.93%
Other operating expenses
-
-
-1.00M
-3.00M
Net income
47.00M
18.00M
42.00M
102.00M
Net profit margin
17.67%
5.96%
13.38%
28.49%
Earnings per share
0.41
0.51
0.72
0.82
Interest and investment income
4.00M
6.00M
6.00M
6.00M
Interest expense
-12.00M
-15.00M
-12.00M
-6.00M
Net interest expenses
-8.00M
-9.00M
-6.00M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
73.00M
71.00M
119.00M
135.00M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more